Neumora Therapeutics (NMRA) investor relations material

Obesity and NLRP3 Inhibitor Program

• NLRP3 inhibitor targets CNS-mediated pathways to suppress appetite, offering a novel mechanism distinct from incretins and amylins.

• Oral, once-daily small molecule formulation aims for high brain penetration, improved tolerability, and affordability compared to injectables.

• Upcoming DIO mouse model data expected later this year will inform clinical development, with monotherapy, combination, and maintenance paradigms under evaluation.

• Plans to enter clinical trials in 2026, starting with monotherapy and expanding to combination and maintenance studies if preclinical data supports.

• Potential benefits include lean muscle mass sparing, reduced GI side effects, and broader metabolic and cardiovascular utility.

M4 PAM Franchise and Clinical Strategy

• Two M4 positive allosteric modulators (PAMs) are advancing, with one in phase 1 and another entering the clinic by year-end, both optimized for brain penetration and safety.

• The franchise approach allows for targeting multiple neuropsychiatric and neurodegenerative indications, including schizophrenia and dementia-related psychosis.

• Phase 1 studies include stable schizophrenia patients to assess dose tolerance, PK, and side effect profiles, with prioritization of the lead asset for proof-of-concept studies.

• Early data will guide whether both assets pursue schizophrenia or diverge into other indications.

Updates on Coastal and 511 Programs

• Coastal studies were paused and refined to improve patient selection and site quality, with new screening processes to ensure higher data integrity.

• Enrollment guidance for COSTAL 2 and 3 remains for 2026, with operational changes expected to address prior placebo response issues.

• The 511 program targets Alzheimer's agitation, with phase 1b data expected by year-end; aims for better tolerability than current therapies and focuses on outpatient populations.